Business
INVO Bioscience Achieves Key Milestone - Signs Agreement to Open First Joint Venture INVOcell Clinic in the United States
INVO has partnered with experienced reproductive specialists who are strong advocates of the INVOcell solution Clinic to be located in Birmingham, Alabama
About this update from Invo Fertility, Inc.
[{"type":"text","content":"INVO has partnered with experienced reproductive specialists who are strong advocates of the INVOcell solution\n Clinic to be located in Birmingham, Alabama with a focus on providing INVOcell as an efficient, effective and affordable fertility treatment option for the very large underserved patient population in need of care\n\n\nSARASOTA, Fla. and BIRMINGHAM, Ala., March 15, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the signing of a 50/50 joint venture agreement in partnership with reproductive specialists Dr. Nicholas Cataldo, MD, MPH, Dr. Karen R. Hammond, DNP, CRNP, and Lisa Ray, MS, ELD, to open the first Joint Venture INVO-exclusive clinic in the United States. The INVO clinic will be located in Birmingham, Alabama and is expected to be operational in the second half of 2021.\n\n \n \n \n \n \n \n\n \nSteve Shum, CEO of INVO Bioscience, commented, \"This is an important milestone for INVO Bioscience as we plan the opening of the first Joint Venture INVOcell-exclusive clinic in the United States in partnership with leading reproductive specialists. The exclusive clinic model creates a unique opportunity for INVO and our partners to drive accelerated adoption of the INVOcell solution while increasing the capacity of the infertility industry, improving affordability, and facilitating greater access for patients. We are fortunate to partner with such high caliber partners as Drs. Cataldo, Hammond and Ray, who are extremely well-versed in the INVOcell technology and have a proven track record of successful implementation within a thriving clinical setting. We believe their expertise will be invaluable as we build a successful operating model which can be replicated for additional INVOcell-exclusive clinics. We look forward to reporting on those additional activities in the near future,\" concluded Shum.\nTogether, the team of Cataldo, Hammond, and Ray has been one of the IVF industry's leading advocates of the INVOcell solution. Since 2018, they have performed more than 700 cycles with INVOcell with patients traveling to Birmingham from more than 28 states across the country to access the procedur...